CTTH - CTT Pharma Gives Update on NSF Grant for Smoke Reduction Technology
(TheNewswire)
Tampa, Florida, United States – The Newswire – June 2 5 , 2024 - CTTPharmaceutical Holdings, Inc. (OTC:CTTH) submitted a full proposal tothe National Science Foundation(NSF) for our patented fast dissolvingnicotine strips. The NSF grant program is highly competitive as itreceives over 12,000 applicants annually from companies that haveinnovations that could help society. CTT successfully made it past thefirst round process and is among a few thousand remaining applicants.These remaining applicants have several deadlines over the course ofthe year to file a full proposal into the grant program. CTTsuccessfully met the March 4 th deadline and is anticipating an answer in the last week ofAugust or the first week of September. Successful entry into the allthree phases with the NSF grant program would allow CTT funding forthe creation of our technology, research/testing, and mass productionof our low dose fast acting dissolvable nicotine strips.
The World Health Organization states, “The tobaccoepidemic is one of the biggest public health threats the worldhas ever faced, killing over 8 million people a year around the world.More than 7 million of those deaths are results of direct tobacco usewhile 1.3 million are the result of non-smokers being exposed tosecond- hand smoke.” Furthermore, the CDC says,“Cigarette smoking is the leading cause of preventable deathin the United States. Cigarette smoking causes more than 480,000deaths each year in the United States. This is nearly 1 in 5 deaths.
The CEO of CTT Pharma, Ryan Khouri, stated to make it past the firstround of applicants is a huge accomplishment by itself and shows thatthe NSF sees value for our technology within the tobacco industry.Currently there are no fast dissolving, low dose nicotine strips onthe market, as most oral products stay in the mouth for an excessiveamount of time. I’m optimistic about thisopportunity and will continue to pursue the NSF in the event that wedo not get approval. I want shareholders to know that we will alsogive updates on our NIH Grants in the near future. The NIH Grant is a$15 million award for a smoking cessation product that would involvehuman trials with Johns Hopkins University using our patentedtechnology. The other grant is for a $2.3 million and is for adiabetes patients using liraglutide on a dissolvable strip andpotentially allowing diabetic patients and people battling obesity analternative to daily or weekly injections.
CTT Pharma – 813-606-0060
Copyright (c) 2024 TheNewswire - All rights reserved.